Don't Worry About Missing The Bottom
Eli Inkrot - at Seeking Alpha - Thu Dec 25, 1:41PM CST
KMI: 42.01 (+0.10), JNJ: 104.59 (+0.31), GE: 25.83 (-0.05), PG: 93.14 (-0.15), AFL: 61.94 (unch)
Final Glance: Pharmaceuticals companies
AP - Wed Dec 24, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 104.59 (+0.31), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01)
Final Glance: Medical Devices companies
AP - Wed Dec 24, 5:02PM CST
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 114.11 (+0.64), JNJ: 104.59 (+0.31), MDT: 74.08 (+0.31), BAX: 74.45 (-0.04)
Integra LifeSciences Hits 52-Week High on Portfolio Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 12:00PM CST
Over the last few months, Integra LifeSciences Holdings Corporation (IART) has launched back-to-back products which we believe will enhance the overall product portfolio and also usher in more profitability for the company.
ZMH: 114.11 (+0.64), JNJ: 104.59 (+0.31), IART: 53.68 (+0.32), SYK: 96.00 (-0.61)
Early Glance: Pharmaceuticals companies
AP - Wed Dec 24, 9:23AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
JNJ: 104.59 (+0.31), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01)
Early Glance: Medical Devices companies
AP - Wed Dec 24, 9:23AM CST
NEW YORK (AP) — Shares of some top medical devices companies are up at 10 a.m.:
ZMH: 114.11 (+0.64), JNJ: 104.59 (+0.31), MDT: 74.08 (+0.31), BAX: 74.45 (-0.04)
The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 24, 8:03AM CST
For shareholders of Gilead Sciences it's practically been a dream year . Shares rose close to 40%, tacking on roughly $45 billion in market value, following the successful approval and launch of oral hepatitis C drugs Sovaldi and Harvoni. ...
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
4 Reasons I'm Adding Gilead To My Healthcare Holdings
Brian Nichols - at Seeking Alpha - Wed Dec 24, 6:18AM CST
JNJ: 104.59 (+0.31), ACAD: 30.95 (+0.78), GILD: 91.29 (+1.84), CLDX: 17.08 (-0.18)
Use of Composites in Orthopedic Industry to Reach $596 Million by 2020
PR Newswire Europe - Wed Dec 24, 3:57AM CST
NEW YORK and LONDON, December 24, 2014 /PRNewswire/ --
SNN: 38.18 (+0.14), JNJ: 104.59 (+0.31), MDT: 74.08 (+0.31), NUVA: 47.37 (+0.78), SYK: 96.00 (-0.61)
Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 5:05PM CST
Pharmacyclics, Inc. (PCYC) announced that the FDA is expected to render a final opinion on the supplemental New Drug Application for Imbruvica for WM indication by Apr 17, 2015.
AGN: 210.12 (+0.95), JNJ: 104.59 (+0.31), ACT: 254.20 (-1.68), PCYC: 121.84 (+1.15)
Achillion Gains on Positive Results from its HCV Candidates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:00PM CST
Achillion Pharmaceuticals (ACHN) gained more than 9% after announcing encouraging results from its HCV candidates.
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), AMGN: 160.67 (+3.15)
Express Scripts (ESRX) Picks AbbVie's Hepatitis C Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:50PM CST
Pharmacy benefit manager Express Scripts (ESRX) announced an update to its National Preferred Formulary, which will now include AbbVie's (ABBV) recently approved new medication for hepatitis C, Viekira Pak.
JNJ: 104.59 (+0.31), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), CRL: 63.59 (+0.33)
AbbVie Puts The Hurt On Gilead Sciences, Closes Exclusive Deal With Express Scripts
Kal Telage - at Seeking Alpha - Tue Dec 23, 3:41PM CST
JNJ: 104.59 (+0.31), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86)
Johnson & Johnson Set to Possibly Rebound After Yesterday's Selloff of 2.30%
Comtex SmarTrend(R) - Tue Dec 23, 3:41PM CST
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $103.92 to a high of $106.91. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $104.74 on volume of 10.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 104.59 (+0.31)
Look for Shares of Johnson & Johnson to Potentially Rebound after Yesterday's 2.30% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 3:40PM CST
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $103.92 to a high of $106.91. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $104.74 on volume of 10.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 104.59 (+0.31)
My 10 Stocks For A Young Dividend Growth Investor
Integrator - at Seeking Alpha - Tue Dec 23, 2:02PM CST
SBUX: 81.27 (-0.16), JNJ: 104.59 (+0.31), V: 267.63 (+2.37), HSY: 106.28 (-0.36), DIS: 94.42 (-0.27), COST: 143.65 (-0.50), COP: 70.13 (-0.92), VZ: 47.67 (unch), PEP: 97.09 (-0.27), CL: 70.47 (-0.53)
MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:00PM CST
MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development and commercialization of MGD011.
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31), MDCO: 27.06 (+0.21), BMY: 59.15 (-0.01), FPRX: 26.12 (+0.07)